IT 235 companion diagnostic - Intezyne
Latest Information Update: 25 Jul 2023
Price :
$50 *
At a glance
- Originator Intezyne
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 25 Jul 2023 Discontinued - Preclinical for Solid tumours (Diagnosis) in USA (unspecified route)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA
- 15 Nov 2017 IT 235 companion diagnostic - Intezyne is available for licensing as of 15 Nov 2017. www.Intezyne.com